PubMed Health⌕ Search

PubMed · 11669961

A Triangular Copper(I) Complex Displaying Allosteric Cooperativity in Its Electrochemical Behavior and a Mixed-Valence Cu(I)-Cu(I)-Cu(II) State with Unusual Temperature-Dependent Behavior.

Abstract

Reaction of the tris-chelating hexadentate podand ligand tris[3-(2-pyridyl)pyrazol-1-yl]hydroborate (Tp(Py)) with [Cu(MeCN)(4)][PF(6)] affords [Cu(I)(3)(Tp(Py))(2)][PF(6)] (1), which was crystallographically characterized. 1.(MeCN)(2): C(52)H(44)B(2)Cu(3)F(6)N(20)P, orthorhombic, Pna2(1); a = 24.592(7), b = 16.392(5), c = 13.365(5) Å; Z = 4. Each Cu(I) ion is four coordinated by one N,N '-bidentate arm from each ligand; each ligand therefore donates each bidentate arm to a different Cu(I) ion. The isosceles triangular arrangement of Cu(I) ions with N-donor ligands is reminiscent of the tricopper(I) site of ascorbate oxidase. One-electron oxidation of 1 affords the Cu(I)(2)Cu(II) complex [Cu(3)(Tp(Py))(2)][PF(6)](2) (2). The potentials of the Cu(I)/Cu(II) redox couples are affected by the ease with which the accompanying geometric rearrangement can occur. Thus, the first oxidation of 1 is facile (-0.52 V vs the ferrocene/ferrocenium couple, Fc/Fc(+)), but as a result of the concomitant structural rearrangement the second oxidation is rendered much more difficult (+0.12 V vsFc/Fc(+)) and results in slow decomposition of the product. A third oxidation does not occur at accessible potentials. This complex therefore exhibits negative cooperative behavior, in which the geometric change accompanying one metal-based redox change hinders further redox changes at other sites via an allosteric effect. EPR studies on the mixed-valence complex 2 show that in frozen glasses below 120 K the unpaired electron is delocalized over two metal centers (7-line spectrum), but above 160 K the electron becomes localized and gives a simple axial spectrum. The electronic spectrum of 2 in solution shows an intense band at 910 nm (epsilon 2100 dm(3) mol(-)(1) cm(-)(1)) which we believe to be an IVCT band. The combination of EPR and electronic spectral studies show that 2 is class III (fully delocalized over 2 centers) below 120 K but class II (localized but strongly interacting) at higher temperatures.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Peter L. Jones, John C. Jeffery, John P. Maher, Jon A. McCleverty, Philip H. Rieger, Michael D. Ward. 1997-07-02. A Triangular Copper(I) Complex Displaying Allosteric Cooperativity in Its Electrochemical Behavior and a Mixed-Valence Cu(I)-Cu(I)-Cu(II) State with Unusual Temperature-Dependent Behavior.. https://doi.org/10.1021/ic970088q

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Effectiveness of high-dose versus standard-dose influenza vaccines against hospitalisation according to frailty risk: a prespecified analysis of the randomised trial DANFLU-2.

BACKGROUND: Frailty is a major risk factor for influenza-related complications and can influence vaccine effectiveness. We aimed to assess the relative vaccine effectiveness (rVE) of high-dose (HD-IIV) versus standard-dose inactivated influenza vaccine (SD-IIV) in older adults aged 65 years or older according to frailty risk. METHODS: This study was a prespecified analysis of DANFLU-2, an open-label, individually randomised trial, conducted in Denmark during three consecutive influenza seasons (2022-23, 2023-24, and 2024-25). Adults aged 65 years or older were randomised (1:1) to the HD-IIV or SD-IIV group. The primary endpoint was hospitalisation for influenza or pneumonia. Frailty was defined according to the validated Hospital Frailty Risk Score (HFRS) based on ICD-10 codes within 10 years before randomisation. Participants were stratified into three HFRS categories, namely low (<5 points), intermediate (5-15 points), and high (>15 points) frailty risk. The rVE of HD-IIV versus SD-IIV against the primary endpoint was assessed across prespecified HFRS categories and treating HFRS as a continuous variable. Pearson's chi-square test was used to compare safety events across frailty risk groups and randomisation groups. FINDINGS: Among 332&#x2009;438 randomised participants (mean age 73&#xb7;7 years [SD 5&#xb7;8]; 161&#x2009;538 [48&#xb7;6%] were female), 276&#x2009;173 (83&#xb7;1%) had low frailty risk, 52&#x2009;395 (15&#xb7;8%) had intermediate frailty risk, and 3861 (1&#xb7;2%) had high frailty risk. The primary endpoint of hospitalisation for influenza or pneumonia occurred in 1424 (0&#xb7;5%) of 276&#x2009;173 participants with low frailty risk, 761 (1&#xb7;5%) of 52&#x2009;395 with intermediate frailty risk, and 163 (4&#xb7;2%) of 3861 with high frailty risk (relative risk [RR] for intermediate vs low frailty risk 2&#xb7;8 [95% CI 2&#xb7;6-3&#xb7;1]; RR for high vs low frailty risk 8&#xb7;2 [7&#xb7;0-9&#xb7;6]). HFRS as a continuous variable significantly modified the effect of HD-IIV versus SD-IIV against the primary endpoint with higher rVE estimates with increasing HFRS (pinteraction=0&#xb7;020). The rVE was 0&#xb7;2% (95% CI -10&#xb7;8 to 10&#xb7;2) among those with low frailty risk, 13&#xb7;1% (-0&#xb7;4 to 24&#xb7;8) among those with intermediate frailty risk, and 19&#xb7;9% (-10&#xb7;3 to 42&#xb7;1) among those with high frailty risk. No significant interaction was observed when HFRS was assessed according to the prespecified categorical frailty groups (pinteraction=0&#xb7;17). The proportion of participants with at least one serious adverse event increased across frailty risk groups (13&#x2009;366 [4&#xb7;8%] of 275&#x2009;795 for low frailty risk, 5475 [10&#xb7;5%] of 52&#x2009;315 for intermediate frailty risk, and 777 [20&#xb7;2%] of 3850 for high frailty risk; p<0&#xb7;0001), with similar proportions of serious adverse events in the HD-IIV and SD-IIV groups for each frailty risk group. INTERPRETATION: Among adults aged 65 years or older in Denmark, frailty risk might modify the effects of HD-IIV versus SD-IIV against hospitalisation for influenza or pneumonia, with higher rVE estimates with increasing frailty risk. These findings might support considering high-dose influenza vaccines for frail older adults. However, effect modification was not evident when frailty was assessed using prespecified categorical subgroups, and subgroup-specific estimates were imprecise, with 95% CIs crossing the null. These results should be considered exploratory, warranting further investigation. FUNDING: The DANFLU-2 trial was funded by Sanofi.

Journal Article↗